Incretin-based therapy in chronic kidney disease.
Type 2 diabetes mellitus (T2DM) with concomitant CKD is an emerging clinical and public health problem reaching epidemic proportions in the United States. Achieving and maintaining glycemic targets in clinical practice are significant challenges in majority of the patients with T2DM and CKD, and this has created significant barriers for clinicians managing these patients. Commonly used antihyperglycemic agents are either contraindicated or lack efficacy and safety information in this population. Recently, 2 distinct classes of agents that augment incretin hormone action have been added to the therapeutic armamentarium targeting hyperglycemia. This review will discuss the literature examining the efficacy and safety of incretin-based therapies in T2DM and the available evidence for their use in CKD.
Pinelli
Nicole R
NR
Department of Pharmacy Practice, Wayne State University, Detroit, MI 48201-2427, USA. nickipinelli@wayne.edu
Moore
Carol L
CL
Tomasello
Sarah
S
D001786:Blood Glucose / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D003928:Diabetic Nephropathies / Q000097:blood / Q000453:epidemiology / Q000209:etiology / Q000628:therapy / Q000652:urine; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D054795:Incretins / Q000494:pharmacology; D051436:Renal Insufficiency, Chronic / Q000097:blood / Q000453:epidemiology / Q000209:etiology / Q000628:therapy / Q000652:urine; D016896:Treatment Outcome
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D054795:Incretins